Moreover, the 36-month beta value for ATYR is 1.05. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATYR is 73.81M and currently, short sellers hold a 1.44% of that float. On November 08, 2024, ATYR’s average trading volume was 744.86K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATYR) stock’s latest price update
Atyr Pharma Inc (NASDAQ: ATYR)’s stock price has soared by 0.65 in relation to previous closing price of 3.10. Nevertheless, the company has seen a gain of 2.63% in its stock price over the last five trading days. seekingalpha.com reported 2024-10-24 that aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without immune suppression, setting it apart from traditional treatments, with promising post-hoc results in higher doses. aTyr is well-funded with $81 million in cash, sufficient for upcoming trial readouts, and has seen significant stock performance and insider buying.
ATYR’s Market Performance
ATYR’s stock has risen by 2.63% in the past week, with a monthly rise of 47.17% and a quarterly rise of 72.38%. The volatility ratio for the week is 7.59% while the volatility levels for the last 30 days are 9.54% for Atyr Pharma Inc. The simple moving average for the past 20 days is 1.70% for ATYR’s stock, with a 62.00% simple moving average for the past 200 days.
Analysts’ Opinion of ATYR
Many brokerage firms have already submitted their reports for ATYR stocks, with Wells Fargo repeating the rating for ATYR by listing it as a “Overweight.” The predicted price for ATYR in the upcoming period, according to Wells Fargo is $17 based on the research report published on October 04, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ATYR reach a price target of $9. The rating they have provided for ATYR stocks is “Buy” according to the report published on September 05th, 2024.
ATYR Trading at 33.32% from the 50-Day Moving Average
After a stumble in the market that brought ATYR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.22% of loss for the given period.
Volatility was left at 9.54%, however, over the last 30 days, the volatility rate increased by 7.59%, as shares surge +36.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +60.85% upper at present.
During the last 5 trading sessions, ATYR remain unchanged, which changed the moving average for the period of 200-days by +96.13% in comparison to the 20-day moving average, which settled at $3.06. In addition, Atyr Pharma Inc saw 121.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATYR starting from SCHIMMEL PAUL, who purchase 52,300 shares at the price of $1.93 back on Jul 24 ’24. After this action, SCHIMMEL PAUL now owns 413,023 shares of Atyr Pharma Inc, valued at $101,038 using the latest closing price.
SCHIMMEL PAUL, the Director of Atyr Pharma Inc, purchase 41,052 shares at $1.74 during a trade that took place back on Jul 22 ’24, which means that SCHIMMEL PAUL is holding 354,075 shares at $71,500 based on the most recent closing price.
Stock Fundamentals for ATYR
Current profitability levels for the company are sitting at:
- -106.34 for the present operating margin
- -3.34 for the gross margin
The net margin for Atyr Pharma Inc stands at -98.46. The total capital return value is set at -0.66. Equity return is now at value -61.64, with -48.51 for asset returns.
Based on Atyr Pharma Inc (ATYR), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -4.58.
Currently, EBITDA for the company is -52.18 million with net debt to EBITDA at -0.12. When we switch over and look at the enterprise to sales, we see a ratio of 409.55. The receivables turnover for the company is 0.36for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.63.
Conclusion
To wrap up, the performance of Atyr Pharma Inc (ATYR) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
